abstract nowadays, bypassing agents such as recombinant activated factor vii (rfviia) and activated prothrombin complex concentrates (apcc) are used to treat bleeding episodes in the hemophilia patients with inhibitors. aryoseven® is an iranian biogeneric rfviia with homogeneity of efficacy and the nature to novoseven in a comparative trial. the current clinical trial aimed to evaluate the cost...

The treatment of intracerebral hemorrhage (ICH) has been a largely neglected item. In contrast to literally dozens of clinical trials of treatment of ischemic stroke, only a handful have addressed treatment of ICH with either medical (steroids,1 osmotic diuretics2) or surgical3 interventions. The medical intervention trials, primarily aimed at reducing brain edema surrounding the ICH, have show...

INTRODUCTION Acquired haemophilia A is a rare life- and limb-threatening bleeding disorder if left untreated. Autoimmune thyroiditis is an autoimmune disorder that can be rarely associated with acquired haemophilia. Here we report a case of a 60-year-old woman presenting with cutaneous and muscle haematomas secondary to acquired haemophilia A in association with autoimmune thyroiditis, who was ...

Recombinant factor VIIa (rFVIIa, NovoSeven) is effective and appears safe in the management of bleeding episodes and provision of surgical cover in haemophilia patients with inhibitors. Additionally, rFVIIa has been considered as a universal haemostatic agent, prompting its use in the management of severe uncontrolled surgical bleeding in patients without pre-existing coagulopathies. Recombinan...

BACKGROUND There is increasing use of rFVIIa (eptagog alpha, Novoseven) in injured patients with critical bleeding. The role of rFVIIa is not defined in this group of patients. Registries provide an opportunity to review the patients, reported response and adverse events for rFVIIa. AIM To determine the pattern of use, reported response and adverse events in patients receiving rFVIIa followin...

BACKGROUND Traumatic coagulopathy contributes to early death by exsanguination and late death in multiple organ failure. Recombinant Factor VIIa (rFVIIa, NovoSeven) is a procoagulant that might limit bleeding and improve trauma outcomes. METHODS We performed a phase 3 randomized clinical trial evaluating efficacy and safety of rFVIIa as an adjunct to direct hemostasis in major trauma. We stud...

Introduction Haemophilia A is a congenital bleeding disorder due to the lack of coagulation factor VIII (FVIII). The standard treatment is based on administration of plasma-derived or recombinant FVIII concentrates. The natural history of the disease includes recurrent bleeding into joints and the major long-term disability in affected patients is chronic arthropathy. The life expectancy of pat...